✦ LIBER ✦

Bevacizumab-containing Chemotherapy is Safe in Patients with Unresectable Metastatic Colorectal Cancer and a Synchronous Asymptomatic Primary Tumor

✍ Scribed by Cetin, B.; Kaplan, M. A.; Berk, V.; Tufan, G.; Benekli, M.; Isikdogan, A.; Ozkan, M.; Coskun, U.; Buyukberber, S.

Book ID: 119956280
Publisher: Oxford University Press
Year: 2012
Tongue: English
Weight: 150 KB
Volume: 43
Category: Article
ISSN: 0368-2811
DOI: 10.1093/jjco/hys175

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Hypertension and overall survival in met

Hypertension and overall survival in metastatic colorectal cancer patients treated with bevacizumab-containing chemotherapy

✍ Österlund, P; Soveri, L-M; Isoniemi, H; Poussa, T; Alanko, T; Bono, P 📂 Article 📅 2011 🏛 Nature Publishing Group 🌐 English ⚖ 320 KB

Clinical significance of primary tumor r

Clinical significance of primary tumor resection in colorectal cancer patients with synchronous unresectable metastasis

✍ Kim, Min Sung; Chung, MinKyu; Ahn, Joong Bae; Kim, Chang Woo; Cho, Min Soo; Shin 📂 Article 📅 2014 🏛 John Wiley and Sons 🌐 English ⚖ 173 KB

Primary mFOLFOX6 Plus Bevacizumab Withou

Primary mFOLFOX6 Plus Bevacizumab Without Resection of the Primary Tumor for Patients Presenting With Surgically Unresectable Metastatic Colon Cancer and an Intact Asymptomatic Colon Cancer: Definitive Analysis of NSABP Trial C-10

✍ McCahill, L. E.; Yothers, G.; Sharif, S.; Petrelli, N. J.; Lai, L. L.; Bechar, N 📂 Article 📅 2012 🏛 American Society of Clinical Oncology 🌐 English ⚖ 209 KB

Survival and symptomatic benefit from pa

Survival and symptomatic benefit from palliative primary tumor resection in patients with metastatic colorectal cancer: a review

✍ Andrew Eisenberger; R. Lawrence Whelan; Alfred I. Neugut 📂 Article 📅 2008 🏛 Springer 🌐 English ⚖ 187 KB

Is primary tumor resection associated wi

Is primary tumor resection associated with a longer survival in colon cancer and unresectable synchronous metastases? A 4-year multicentre experience

✍ de Mestier, L.; Neuzillet, C.; Pozet, A.; Desot, E.; Deguelte-Lardière, S.; Vole 📂 Article 📅 2014 🏛 Elsevier Science 🌐 English ⚖ 275 KB

Pharmacogenetic profiling of CD133 is as

Pharmacogenetic profiling of CD133 is associated with response rate (RR) and progression-free survival (PFS) in patients with metastatic colorectal cancer (mCRC), treated with bevacizumab-based chemotherapy

✍ Pohl, A; El-Khoueiry, A; Yang, D; Zhang, W; Lurje, G; Ning, Y; Winder, T; Hu-Lie 📂 Article 📅 2012 🏛 Nature Publishing Group 🌐 English ⚖ 401 KB